Advertisement
Advertisement

TheBodyPRO.com covers CROI 2014

Abacavir Link to Cardiovascular Events in High-Risk Patients Maintained in D:A:D Study

March 24, 2014

A poster at CROI 2014, presented by Caroline Sabin from University College London and colleagues, presented follow-up results from D:A:D since the initial findings in 2008 of a link between abacavir use and risk of myocardial infarction (MI) in people with high cardiovascular risk.1

Given the high profile given to the initial results, abacavir should have been less likely to be prescribed in high CVD risk patients, with any confounding bias now working against seeing a continued association.

UK guidelines no longer recommend using abacavir in HIV positive people who have a high risk of cardiovascular disease (CVD), defined as >20% 10-year Framingham score.2 This is based on results from cohort studies that have reported an association, the largest of these being the prospective D:A:D study that was designed to look at ARVs and CVD and that first reported this associated at CROI in 2008.3

Advertisement
In this study, logistic regression models were used to compare CVD and abacavir use before and after March 2008.

When stratifying abacavir use, people at moderate or high CVD risk were more likely to use abacavir before March 2008 (aOR 1.14; 95%CI: 0.90, 1.44) and less likely to use it afterwards (aOR 0.74; 95%CI: 0.48, 1.13), p=0.007 for interaction. After March 2008, people at moderate/high CVD risk on abacavir were more likely to discontinue abacavir than those at low/unknown CVD risk (relative rate (RR) 1.49 [95% CI 1.34-1.65]).

In the new analysis, the rate of MI with current use of abacavir was 0.47 (95%CI: 0.42-0.52) compared to 0.21 (95%CI: 0.19-0.22) without, with abacavir associated with a 98% increase in MI (RR 1.98; 95%CI: 1.72-2.29). There was no difference in the early and late periods and results were unchanged after adjusting for other CVD-related factors.


Comment

It is notable that the D:A:D group took five years after the initial findings to accumulate sufficient new data to reassess this association.


Reference

  1. Sabin C et al. Is there continued evidence for an association between abacavir and myocardial infarction risk? 21st CROI, 3-6 March 2014, Boston. Poster abstract 747 LB.



This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
 


No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement